Fast Facts: Prostate Cancer
Prostate cancer is the second most common cancer in men worldwide, but it is unusual among solid tumors in that many men die with, rather than of, the disease. This raises challenges in terms of deciding if, when, and how to intervene to control tumor growth and spread in order to extend survival wi...
| Autores principales: | , |
|---|---|
| Formato: | Libro |
| Publicado: |
S. Karger
2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=nlebk&AN=4328797&site=ehost-live header: @attributes: shortDbName: nlebk uiTerm: 4328797 longDbName: eBook Collection (EBSCOhost) uiTag: AN controlInfo: bkinfo: btl: Fast Facts: Prostate Cancer aug: au: Manish I. Patel Darren M. C. Poon imageinfo: pubinfo: dt: @attributes: year: 2024 month: 01 day: 01 ed: 11th edition pub: S. Karger pubContract: Karger AG (Open Access) place: Basel price: 0.01 limitsGroup: maxCheckoutDays: 1500 pda: N printPagesOffline: 100 printPagesOnline: 100 previewPages: 10000 artinfo: ui: 4328797 1426840411 formats: fmt: @attributes: type: EK doid: NL$4328797$EPUB caption: EPUB download: Y tig: atl: Fast Facts: Prostate Cancer ptl: Fast Facts aug: au: Manish I. Patel Darren M. C. Poon sug: subj: MEDICAL / Oncology / General ab: Prostate cancer is the second most common cancer in men worldwide, but it is unusual among solid tumors in that many men die with, rather than of, the disease. This raises challenges in terms of deciding if, when, and how to intervene to control tumor growth and spread in order to extend survival without compromising quality of life. The many developments in the field since the last edition of this book include continuing studies to improve detection and monitoring of the disease, with the evaluation of MRI for screening and prostate-specific membrane antigen (PSMA)-PET/CT for staging. Treatment options have also continued to improve and expand for all stages of the disease with the development of ultrahypofractionated radiotherapy, oral LHRH antagonists, PARP inhibitors and lutetium-177 PSMA-617 radioligand therapy. pubtype: eBook doctype: Book ougenre: Book language: English copyright: @attributes: flag: N copyrightText: holdings: @attributes: islocal: N |
|---|